



## ESOCAP ANNOUNCES ISSUE OF A PATENT IN JAPAN FOR ITS UPPER GASTROINTESTINAL TRACT SMART APPLICATION TECHNOLOGY

*Basel, Switzerland, July 8, 2020*

**EsoCap AG announced today that the Japanese Patent and Trademark Office issued a patent under number 6719471 on June 18, 2020, based on international patent PCT/EP2015/002601.**

The patent is directed at the smart application technology enabling effective topical treatment of several diseases of the esophagus. "Issue of the Japanese patent confirms the novelty of EsoCap's technology", commented Isabelle Racamier, EsoCap AG CEO. Under a worldwide agreement, the University of Greifswald in Germany has granted EsoCap the exclusive rights to this unique drug delivery technology developed by the University of Greifswald. Up to now, local treatment of diseases of the esophagus was not possible due to the ultra-short transit time of conventional drug formulations.

"We believe that grant of this additional patent, following on from the issue in Russia and South Africa, strengthens EsoCap's commitment to development of its smart application technology, which will be beneficial in at least six esophageal diseases affecting 370 million patients", said Dr Peter Stangier, Director Strategic Planning at EsoCap AG.

### About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short drug contact time of one to two seconds from the mouth to the stomach.

EsoCap owns and develops a unique drug delivery platform allowing the efficient topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit [www.esocapbiotech.com](http://www.esocapbiotech.com).

### Contact:

Isabelle Racamier, CEO

EsoCap AG  
Malzgasse 9  
4052 Basel  
Switzerland

[isabelle.racamier@esocapbiotech.com](mailto:isabelle.racamier@esocapbiotech.com)